CHARLEROI, Belgium--(BUSINESS WIRE)--Delphi Genetics SA (“Delphi”) has announced today the signature of a licensing agreement with GlaxoSmithKline (GSK) for the use of the patented StabyExpress technology for the production of protein vaccines for human use.
